2seventy, Bristol Myers Squibb
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
Inc (NASDAQ:TSVT) and its partner Bristol Myers Squibb & Co (NYSE:BMY), will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study of Abecma (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone for newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant.
Bristol Myers, 2seventy bio halt enrollment in Abecma late-stage trial
Shares of 2seventy bio (NASDAQ:TSVT) lost ~16% in the premarket Wednesday after the cancer drug developer and its partner Bristol Myers Squibb (NYSE:BMY) announced plans to discontinue enrollment in an ongoing Phase 3 trial for their T cell immunotherapy,
BMS and 2seventy bio to discontinue enrolment in multiple myeloma trial
Despite being open for over a year across 18 countries, the trial managed to recruit only 10% of its target population.
Citing enrollment challenges, Bristol Myers and 2seventy scrap Abecma trial in first-line myeloma
Bristol Myers Squibb’s struggling CAR-T therapy Abecma has hit a major setback. | Bristol Myers Squibb’s CAR-T therapy Abecma has hit a major setback. Bristol and its partner 2seventy bio have decided to pull the plug on the phase 3 KarMMa-9 trial in first-line myeloma after struggling to enroll patients.
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM
Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2
2seventy, Bristol Myers Discontinue Enrollment In Phase 3 KarMMa-9 Study - Quick Facts
(RTTNews) - 2seventy bio (TSVT) announced that the company, in partnership with study sponsor Bristol Myers Squibb, will discontinue enrollment
bovnews3h
Uncover the Reason: Why 2Seventy Bio Inc (TSVT) Stock Is Trading 221.17% Above Its 52-Week Low?
On Friday, 2Seventy Bio Inc (TSVT) stock saw a modest uptick, ending the day at $4.93 which represents a slight increase of $0.17 or 3.57% from the prior close of $4.76. The stock opened at $4.83 and ...
Buy Rating Affirmed for 2seventy bio Despite Trial Setback: Niche Market Strategy and Safety Profile Underpin Positive Outlook
Daina Graybosch, an analyst from Leerink Partners, reiterated the Buy rating on 2seventy bio (TSVT – Research Report). The associated ...
Business Wire3d
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will ...
BioPharma Dive3d
Struggling 2Seventy scraps a key cancer study
The biotech expects that stopping enrollment for KarMMa-9, a trial evaluating early use of the multiple myeloma cell therapy Abecma, should save it $80 million in the near term.
Hold Rating on 2seventy bio Amidst Strategic Shifts and Enrollment Challenges
In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on 2seventy bio (TSVT – Research Report), with a ...
The Pharma Letter3d
2seventy bio and BMS to drop KarMMa-9 study
US biotech 2seventy bio and partner Bristol Myers Squibb today revealed that they will discontinue enrollment in its ongoing ...
Leerink Partners上调2Seventy Bio股票目标价
Leerink Partners调整了对2Seventy Bio Inc. (NASDAQ: TSVT)的展望，将该股票的目标价从之前的15.00美元上调至25.00美元，同时维持"优于大市"评级。 此次调整是在KarMMa-9试验终止后做出的，该试验原本预计将成为自体BCMA CAR-T疗法Abecma收入增长的重要贡献者。 根据Leerink Partners的分析，尽管KarMMa-9试验终 ...
2seventy Bio stops enrolling patients in blood cancer therapy study
(Reuters) - 2seventy bio will discontinue enrolling patients in a late-stage study of its cell-therapy Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly ...